Leaflet ELIGARD 45mg powder and solvent for solution for injection

Product code:
W67816001
Quantity:
1
Indicated for:
prostate cancer; breast cancer; endometriosis
Route of administration:
injectable
Substance:
leuprorelin (GnRH agonist)
ATC
L02AE02 — Antineoplastic and immunomodulating agents | Hormones and related agents | Gonadotropin releasing hormone analogues
Leuprorelin is a gonadotropin-releasing hormone (GnRH) agonist used for the treatment of prostate cancer, endometriosis, and precocious puberty. It works by suppressing the production of sex hormones, thereby reducing disease progression.

The medication is administered as a subcutaneous or intramuscular injection, usually once a month or at longer intervals, as directed by a doctor.

Side effects may include hot flashes, decreased libido, fatigue, or bone pain. In rare cases, severe allergic reactions or depression may occur.

Leuprorelin is not recommended for pregnant or breastfeeding women or patients with hypersensitivity to this medication.

General data about ELIGARD 45mg

Substance:
leuprorelin
Date of latest medicines list:
01-06-2026
Product code:
W67816001
Concentration:
45mg
Pharmaceutical form:
powder and solvent for solution for injection
Quantity:
1
Product type:
Original
Price:
1441.53 RON
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
ASTELLAS PHARMA EUROPE BV - OLANDA
Holder:
RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.P.A. - ITALIA
Number:
4208/2012/01
Shelf life:
2 years

Concentrations available for leuprorelin

  • 11.25mg
  • 22.5mg
  • 3.75mg
  • 42mg
  • 45mg
  • 5mg
  • 7.5mg

Compensation lists for ELIGARD 45mg Recipharm

NHP 3 (C2) - NHP oncology

Price
1441.53 RON
Copayment
1441.53 RON
Patient
0.00 RON